Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – (SIX: SANN) announces that the National Institute for ...

NICE’s positive final guidance for Agamree follows confirmation that no appeals were submitted against its positive December ...

Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

The UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends Agamree (vamorolone) for use in the National Health ...

China’s National Medical Products Administration (NMPA) has approved Santhera Pharmaceuticals’ AGAMREE (vamorolone), used to treat Duchenne muscular dystrophy (DMD) in patients aged four years ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy: Pratteln, Switzerland Wednesday, January 15, 2025 ...

Following this, Santhera has already started launch preparations for AGAMREE in the UK and expect first sales in this quarter. AGAMREE is the first and only medicinal product for DMD to have ...

Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy AGAMREE® has been recommended by NICE for treating Duchenne muscular ...